Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological ...
Nasdaq

Voyager Therapeutics Launches New Gene Therapy Program Targeting APOE for Alzheimer's Disease Treatment

Voyager Therapeutics has unveiled a new program focused on Alzheimer’s disease (AD) that utilizes a proprietary IV-delivered TRACER™ capsid to target the APOE gene, specifically aiming to reduce the ...
Nasdaq

Voyager Provides Update on SOD1 ALS Gene Therapy Program

LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to ...